Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses her experience with men who have been treated aggressively for low grade, low volume…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses new research led by the Eastern Cooperative Oncology group looking at a RCT of…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses how radical prostatectomy can provide a definitive cure in many cases of prostate cancer.…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses how prostate cancer requires an integrated multidisciplinary approach. Related ReadingEnhancing prostate cancer care through…
Anna Ferrari, MD, Professor and Co-Director GU Research at NYU Langone Medical Center, discusses the diagnosis of prostate cancer and what a man needs to know. The three…
NEW YORK (Reuters Health) – Brachytherapy is a viable option for prostate cancer patients 60 and younger, the authors of a new report in BJUI conclude. “Prostate cancer…
NEW YORK (Reuters Health) – The tumor volume threshold of 0.5 mL for clinically insignificant prostate cancer, established in the early 1990s, remains valid, according to researchers who…
NEW YORK (Reuters Health) – There appear to be several problems with the current clinical staging criteria for localized prostate cancer, according to a study published online today…
NEW YORK (Reuters Health) – Despite declining use, perineal radical prostatectomy (PRP) yields outcomes that are equal to, or better than, those of retropubic radical prostatectomy (RRP) and…
NEW YORK (Reuters Health) – Men whose baseline PSA is less than 2.0 ng/mL are unlikely to benefit from further screening for prostate cancer, according to findings reported…